<DOC>
	<DOCNO>NCT01874288</DOCNO>
	<brief_summary>An open-label , dose-escalation trial safety , tolerability , pharmacokinetics ( PK ) , biological , clinical activity DI-Leu16-IL2 administer patient CD20 ( B-lymphocyte antigen CD20 ) positive Non-Hodgkin Lymphoma ( NHL ) fail standard rituximab-containing therapy . Following peripheral blood B cell depletion rituximab ( need ) patient receive DI-Leu16-IL2 administer subcutaneous ( SC ) injection three consecutive day every three week .</brief_summary>
	<brief_title>Phase I/II Study De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously Patients With B-cell NHL</brief_title>
	<detailed_description>An open-label , dose-escalation trial safety , tolerability , pharmacokinetics ( PK ) , biological , clinical activity DI-Leu16-IL2 administer patient CD20 ( B-lymphocyte antigen CD20 ) positive Non-Hodgkin Lymphoma ( NHL ) fail standard rituximab-containing therapy . Following peripheral blood B cell depletion rituximab ( need ) patient receive DI-Leu16-IL2 administer subcutaneous ( SC ) injection three consecutive day every three week ( 21 day cycle ) . Three six ( 3-6 ) patient enrol cohort . Patients may receive 6 cycle DI-Leu16-IL2 approximately thrice weekly 3 week total 18 dos . Approximately 66 patient enrol study approximately 6 investigational center U.S. Forty-two ( 42 ) patient enrol dose escalation ( Phase 1 ) 2 expansion cohort 12 patient ( Phase 2 ) . Following completion Phase I portion trial review safety , response correlative immune data elect 2 expansion cohort 12 patient 2 mg/m2 . - Diffuse Large B-Cell Lymphoma ( DLBCL ) relapse refractory standard therapy - All CD20-expressing B-cell NHL relapse refractory standard therapy . As mentioned Chronic Lymphocytic Leukemia ( CLL ) /Small Lymphocytic Lymphoma ( SLL ) peripheral blood leukemia/lymphoma cell high-grade lymphoma ( i.e . Lymphoblastic Lymphoma/Burkitt 's Lymphoma ) exclude At end study , patient may enrol open-label extension study ( Study AO-101-EXT ) , discretion investigator . Study Primary Endpoints 1 . To determine maximum tolerate dose ( MTD ) DI-Leu16-IL2 administer SC follow peripheral blood B cell depletion rituximab patient B-cell NHL . 2 . To investigate optimal biologic dose ( OBD ) DI-Leu16-IL2 follow peripheral blood B cell depletion rituximab patient B-cell NHL , may differ MTD . 3 . To describe toxicity associate propose DI-Leu16-IL2 regimen . Study Secondary Endpoints 1 . To evaluate immunogenicity measure induction DI-Leu16-IL2-specific antibody . 2 . To evaluate PK DI-Leu16-IL2 ( achieve primary portion study ) . 3 . To measure response rate MTD ( and/or OBD ) associate proposed therapy survival endpoint enrol patient .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>1 . Patients CD20expressing Bcell NHL relapse refractory standard therapy . Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma peripheral blood leukemia/lymphoma cell highgrade lymphoma exclude 2 . Patients must receive prior rituximabcontaining therapy . 3 . Evaluable disease . In absence lymphadenopathy , splenomegaly defect measurable extramedullary disease acceptable 4 . Patients receive prior autologous stem cell transplant eligible transplant occur &gt; 6 month ago . 5 . Patients receive prior allogeneic stem cell transplant eligible : 1 . The transplant occur &gt; 6 month ago 2 . There evidence active graft v host disease 3 . Systemic immunosuppressive agent ( include corticosteroid ) receive least 8 week 6 . Age ≥18 year 7 . Karnofsky performance scale ≥70 % 8 . Life expectancy ≥12 week 9 . Adequate baseline function : 1 . Serum creatinine ≤ 1.5 mg/dl 2 . Total white blood cell count ( WBC ) ≥ 3000/µl , absolute neutrophil count ( ANC ) ≥ 1000/µl 3 . Absolute lymphocyte count ≥0.75 x 10^3/µl 4 . Platelet count ≥75,000/µl 5 . Hematocrit ≥ 25 % hemoglobin ≥9 g/100 mL 6 . Alanine aminotransferase ( ALT ) &lt; 2.5 x upper limit normal ( ULN ) 7 . Aspartate aminotransferase ( AST ) &lt; 2.5 x UNL 8 . Total bilirubin ( TBili ) &lt; 1.5 x ULN 9 . Sodium , potassium , phosphorus level bad grade 1 10 . Chest xray ( CXR ) compute tomography CT within 4 week prior Day 1 evidence pulmonary congestion , pleural effusion , pulmonary fibrosis , significant emphysema . If result questionable , patient additional lung function test exclude clinically relevant restriction obstruction . Patients must force expiratory volume ( FEV1 ) Diffusing Capacity Lung Carbon Monoxide ( DLCO ) least 65 % 50 % expect , respectively . 11 . Electrocardiogram ( 12lead ECG ) QTc ≤ 480 m 12 . Cardiac stress test ( e.g. , stress thallium scan , stress echocardiography ) normal result patient suspect coronary artery disease . 10 . Patients participate study use adequate birth control measure ( abstinence , oral contraceptive , barrier method spermicide surgical sterilization ) study participation . Females childbearing potential must negative serum pregnancy test day dose . A female childbearing potential sexually mature woman : 1 ) undergone hysterectomy bilateral oophorectomy ; 2 ) naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month . 11 . Provide write informed consent prior screen procedure 1 . Evidence central nervous system lymphoma lymphomatous meningitis 2 . Prior treatment IL2 within last 5 year 3 . Type I hypersensitivity anaphylactic reaction murine proteins previous infusion rituximab 4 . Pregnant lactate female 5 . An immediate need palliative radiotherapy systemic corticosteroid therapy 6 . Known intercurrent infection ( include hepatitis C virus human immunodeficiency virus condition ) , clinical evidence condition 7 . Actively infected chronic carrier hepatitis B virus demonstrate positive hepatitis B core antibody hepatitis B surface antigen . ( Patients seropositive , i.e . surface antibody positive [ HbsAb ] , permit ) 8 . Other significant active infection . 9 . Major surgery , chemotherapy , investigational agent , radiation within 30 day Day 1 10 . Uncontrolled hypertension ( diastolic great equal 100 mmHg ) hypotension ( systolic less equal 90 mmHg ) 11 . History repeat clinically relevant episode syncope paroxysmal , ventricular , significant arrhythmias 12 . History medically significant ascites require repetitive paracentesis 13 . Previous diagnosis autoimmune disease ( Exceptions : patient autoimmune thyroiditis vitiligo may enrol ) 14 . Organ transplant recipient 15 . History prior therapy serious , uncontrolled medical disorder Investigator 's opinion would impair participation study 16 . Known hypersensitivity Tween80 , human immunoglobulin 17 . Legal incapacity limit legal capacity 18 . Patients bulky lymph node ( LNs ) ( ≥10 cm ) mark splenomegaly ( i.e . extend pelvis cross midline ) . 19 . Circulating level rituximab &gt; 75.0 µg/ml</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>NHL</keyword>
	<keyword>Immunocytokine</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Non-Hodgkin</keyword>
	<keyword>B-cell</keyword>
	<keyword>IL ( interleukin )</keyword>
</DOC>